Whether stronger and physiologically regulated γc expression might accomplish a more robust and expedient immune recovery remains to be answered and may be provided by treatment of XSCID patients with a targeted IL2RG insertion approach. This evidence concerns the gene GC and T-B+ severe combined immunodeficiency due to gamma chain deficiency.